secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2024-01-18T23:59:59+00:00
Accession:  0001193125-24-010177
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma cuts workforce 30%, extends cash runway to end of 2026
-----------------------------------------------------------------

- Workforce reduction of ~30% to prioritize PC14586 development and streamline operations.
- Unaudited cash, cash equivalents, and marketable securities of ~$229M as of Dec 31, 2023.
- Expected non-recurring charges of ~$1.4M for employee severance and benefits, mainly in Q1 2024.
- Cash runway now expected to extend to end of 2026 due to cost savings.
- Registrational Phase 2 trial for PC14586 remains on track to initiate in Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312524010177/0001193125-24-010177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312524010177/d695291d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-010177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer